Spotlight On... Sanofi poaches Novartis exec Nathwani as new CMO; Epizyme CEO maps 5-year plan; CRISPR recruits a CFO; and more...

New Sanofi ($SNY) CEO Olivier Brandicourt is assembling his top team. The pharma giant announced that Novartis ($NVS) vet Ameet Nathwani has been named EVP and group chief medical officer, earning a seat on the executive committee. Nathwani is taking the place of Paul Chew, who's retiring later in the year. Sanofi has been setting the stage for a reorganization. Release

@FierceBiotech: Strike 3: Struggling Xoma jettisons its lead drug after (another) PhIII failure. News | Follow @FierceBiotech

@JohnCFierce: Sarepta has a new date with an FDA AdCom for Duchenne drug eteplirsen. Article | Follow @JohnCFierce

> Epizyme ($EPZM) CEO Robert Bazemore mapped out a 5-year plan for the company, including the development of tazemetostat. Release

> CRISPR Therapeutics has named Marc Becker as its new CFO. He had been the CFO at rEVO Biologics. Release

> Germany's Evotec achieved a preclinical milestone for the work it's doing for Padlock Therapeutics. Release

Medical Device News

@FierceMedDev: BD forms $500M JV with private equity firm Apax to house ailing respiratory biz. More | Follow @FierceMedDev

@VarunSaxena2: FDA loss in Vascular Solution off-label promotion case foreshadowed Amarin settlement. Story | Follow @VarunSaxena2

@EmilyWFierce: Biopharma, Republicans and doctors dig in for fight against new CMS cancer-drug cuts. Article | Follow @EmilyWFierce

> Theranos rival HealthTell raises $26M to support its drop-of-blood diagnostics. More

> Abbott to launch 1,000+ patient trial to standardize traumatic brain injury testing. Story

Pharma News

@FiercePharma: Ceva makes strides toward animal health dominance with strong 2015 sales. More | Follow @FiercePharma

@EricPFierce: More biologics manufacturing capacity comes online in the US. Story | Follow @EricPFierce

@CarlyHFierce: AbbVie's $595M anti-inflammatory deal promises an even bigger battle for psoriasis share. News | Follow @CarlyHFierce

> In a welcome, surprising reversal, pharma's reputation among patients takes an upturn. Story

> Valeant settles the R&O lawsuit that touched off its specialty pharmacy woes. Report

CRO News

> 'Molecule to blame' in fatal French drug study. More

> Icon teams up with a nonprofit to help drive better patient outcomes. Report

> Data collection firm ERT is changing private equity hands. Story

> Swiss CRO PSI stretches its reach into Israel. Article

Pharma Manufacturing News

> Merck hands top manufacturing job to Sanat Chattopadhyay. Report

> Lupin finishes Gavis buy, giving it U.S. manufacturing beachhead. Story

> Bain-backed compounder QuVa gets slapped by FDA for plant failings. Article

> Pfizer expanding API plant in Australia. Item

Pharma Asia News

> Price pressure on drug sales in China accelerates in 2016. Report

> Japan's AMED names 8 projects for pre-designation orphan review. Item

> Carlyle-backed Meinian Onehealth snaps up Ciming for $415M. Story

> China FDA approves Roche's cervical test CINtec. More

> Challenged Benitec moves to get word out on hep B candidate. Article

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.